Physician profile
Robert G Kohn
NPI 1003954066
$17,277.27
in general payments reported to CMS, 2019-2025
47 companies · $3,673 in 2025
The $3,673 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,691 · 2020: $1,643 · 2021: $2,122 · 2022: $1,994 · 2023: $2,810 · 2024: $3,344 · 2025: $3,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,544 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,543.54 |
| Education | $283.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,252.22 | 2021-2025 | |
| Allergan, INC. | $1,126.64 | 2019-2020 | |
| Corium, LLC | $961.74 | 2022-2025 | Azstarys, Adlarity |
| Otsuka America Pharmaceutical, INC. | $926.00 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $872.44 | 2020-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $849.19 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $779.59 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $726.98 | 2019-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $721.32 | 2019-2025 | Trintellix |
| Pfizer INC. | $712.47 | 2023-2025 | |
| Harmony Biosciences LLC | $665.08 | 2021-2025 | Wakix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $441.46 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $420.89 | 2019-2024 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $394.75 | 2021 | |
| Tris Pharma INC | $386.62 | 2020-2025 | Dyanavel Xr |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $371.80 | 2019-2025 | |
| Upsher-Smith Laboratories LLC | $352.29 | 2019-2023 | |
| Neos Therapeutics, LP | $312.76 | 2019-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $286.85 | 2019-2024 | Jornay Pm |
| Alkermes, INC. | $278.36 | 2019-2025 | Aristada, Lybalvi |
| Bausch Health US, LLC | $278.04 | 2019-2023 | Aplenzin, Wellbutrin |
| Lilly USA, LLC | $248.95 | 2019-2025 | Kisunla, Amyvid |
| Amgen INC. | $205.84 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $199.32 | 2019 | |
| Ucb, INC. | $177.84 | 2021-2024 | Briviact |
| Janssen Pharmaceuticals, INC | $173.51 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Adlon Therapeutics L.P. | $156.22 | 2019-2021 | |
| Livanova USA, INC. | $150.44 | 2019-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Biohaven Pharmaceutical Holding Company LTD. | $140.51 | 2022 | |
| Shire North American Group INC | $109.12 | 2019 | |
| Biogen, INC. | $99.27 | 2025 | Zurzuvae |
| Sk Life Science, INC. | $69.44 | 2021 | |
| Impel Pharmaceuticals INC. | $53.47 | 2022-2023 | Trudhesa |
| Avanir Pharmaceuticals, INC. | $51.87 | 2020-2022 | |
| Impel Pharmaceuticals LLC | $44.40 | 2024-2025 | Trudhesa |
| Tempus Ai, INC | $40.57 | 2024 | |
| Idorsia Pharmaceuticals US INC | $34.14 | 2023 | Quviviq |
| Rhodes Pharmaceuticals L.P. | $30.22 | 2019 | |
| Sunovion Pharmaceuticals INC. | $29.08 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.32 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $20.97 | 2022 | |
| Vanda Pharmaceuticals INC. | $20.80 | 2019 | |
| Sumitomo Pharma America, INC. | $19.28 | 2023 | Aptiom |
| Novo Nordisk INC | $17.50 | 2024 | |
| Eisai INC. | $16.02 | 2025 | |
| Vertical Pharmaceuticals, LLC | $14.63 | 2025 | Relexxii |
| Merck Sharp & Dohme LLC | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.